PriceTargets.com logo

ENDRA Life Sciences - NDRA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $50.00
  • Forecasted Upside: 809.09%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.50 As of 12/4/2025 05:00 PM ET
▼ -0.46 (-7.72%)

This chart shows the closing price for NDRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ENDRA Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NDRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NDRA

Analyst Price Target is $50.00
▲ +809.09% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ENDRA Life Sciences in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 809.09% upside from the last price of $5.50.

This chart shows the closing price for NDRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in ENDRA Life Sciences. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
4/21/2025Ascendiant Capital MarketsLower TargetBuy ➝ Buy$75.00 ➝ $50.00
6/7/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$875,000.00 ➝ $700,000.00
3/31/2023HC WainwrightReiterated RatingBuy$787,500.00
11/23/2022Ascendiant Capital MarketsSet Target$371,875.00
4/7/2022HC WainwrightLower TargetBuy$525,000.00 ➝ $437,500.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ENDRA Life Sciences logo
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Read More

Today's Range

Now: $5.50
Low: $5.08
High: $5.83

50 Day Range

MA: $5.85
Low: $4.30
High: $8.12

52 Week Range

Now: $5.50
Low: $2.90
High: $11.96

Volume

386,484 shs

Average Volume

66,835 shs

Market Capitalization

$4.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ENDRA Life Sciences?

The following equities research analysts have issued research reports on ENDRA Life Sciences in the last year: Ascendiant Capital Markets, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for NDRA.

What is the current price target for ENDRA Life Sciences?

0 Wall Street analysts have set twelve-month price targets for ENDRA Life Sciences in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 809.1%. Ascendiant Capital Markets has the highest price target set, predicting NDRA will reach $50.00 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $50.00 for ENDRA Life Sciences in the next year.
View the latest price targets for NDRA.

What is the current consensus analyst rating for ENDRA Life Sciences?

ENDRA Life Sciences currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NDRA, but not buy more shares or sell existing shares.
View the latest ratings for NDRA.

What other companies compete with ENDRA Life Sciences?

Other companies that are similar to ENDRA Life Sciences include Vicarious Surgical, Quoin Pharmaceuticals, IRIDEX, Inspira Technologies OXY B.H.N. and Biotricity. Learn More about companies similar to ENDRA Life Sciences.

How do I contact ENDRA Life Sciences' investor relations team?

ENDRA Life Sciences' physical mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company's listed phone number is (734) 335-0468 and its investor relations email address is [email protected]. The official website for ENDRA Life Sciences is www.endrainc.com. Learn More about contacing ENDRA Life Sciences investor relations.